Immunosuppression after heart and lung transplantation

被引:0
|
作者
Wendler, O [1 ]
Schafers, HJ [1 ]
机构
[1] Univ Saarlandes Kliniken, Abt Thorax & Herz Gefasschirurg, D-66421 Homburg, Germany
关键词
heart transplantation; lung transplantation; immunosuppression;
D O I
10.1007/BF03041972
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
In the last two decades heart and lung transplantation have evolved to an accepted treatment of endstage heart and lung failure. A differentiated immunosuppressive regimen is the long term basis of successful transplantation and must, be adopted to the individual patient. Rejection and immunosuppression with potential side effects must be balanced to achieve optimal outcome in,each patient. In the long-term follow up an efficient diagnosis and treatment of rejection probably also results in reduction of chronic organ failure and improvement of general postoperative results. In cases of vasculopathy after heart transplantation: or obliterative bronchiolitis after lung transplantation alternative; immunosuppressive drugs are options in the medical therapy. We present our postoperative management protocol after heart and lung; ; transplantation. Potential problems, new immunosuppressive options End side-effects effects of immunosuppression are discussed.
引用
收藏
页码:3 / 7
页数:5
相关论文
共 50 条
  • [1] Immunosuppression after heart and lung transplantation: Current status
    Schmauss D.
    Meiser B.
    Der Nephrologe, 2010, 5 (2): : 126 - 132
  • [2] Overview of tacrolimus-based immunosuppression after heart or lung transplantation
    Reichenspurner, H
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2005, 24 (02): : 119 - 130
  • [3] Advances in immunosuppression after lung transplantation
    Borro, J. M.
    MEDICINA INTENSIVA, 2013, 37 (01) : 44 - 49
  • [4] Induction immunosuppression after lung transplantation
    Hachem, Ramsey R.
    CURRENT OPINION IN ORGAN TRANSPLANTATION, 2006, 11 (06) : 617 - 620
  • [5] Guidelines of the International Society of Heart and Lung Transplantation on immunosuppression after heart transplantation. Part II: immunosuppressive regimens
    Bernhardt, A.
    Reichenspurner, H.
    ZEITSCHRIFT FUR HERZ THORAX UND GEFASSCHIRURGIE, 2013, 27 (02): : 126 - 133
  • [6] REJECTION AND IMMUNOSUPPRESSION AFTER HEART-TRANSPLANTATION
    LEONARDI, L
    LUTHY, A
    MONDADA, C
    WASER, M
    LASKE, A
    TURINA, M
    GALLINO, A
    THERAPEUTISCHE UMSCHAU, 1990, 47 (02) : 147 - 151
  • [7] A Need for Targeted Immunosuppression after Lung Transplantation
    Bharat, Ankit
    AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, 2019, 61 (03) : 279 - 280
  • [8] New directions in immunosuppression after heart transplantation
    David A. Baran
    Nature Reviews Cardiology, 2013, 10 : 422 - 427
  • [9] GRAFT PRESERVATION AND IMMUNOSUPPRESSION IN HEART-LUNG TRANSPLANTATION
    BALDWIN, JC
    CLINICAL CHEMISTRY, 1987, 33 (06) : 1056 - 1056
  • [10] Induction immunosuppression for combined heart-lung transplantation
    Hayes, Don, Jr.
    McConnell, Patrick I.
    Yates, Andrew R.
    Tobias, Joseph D.
    Galantowicz, Mark
    Mansour, Heidi M.
    Tumin, Dmitry
    CLINICAL TRANSPLANTATION, 2016, 30 (10) : 1332 - 1339